🇺🇸 Artiva Biotherapeutics, Inc.ARTV
Get Artiva Biotherapeutics, Inc. filings on Telegram the moment they are published.
Follow Artiva Biotherapeutics, Inc. on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 8-K Items 2.02, 2.05, 9.01
Overview: Discontinues AlloNK (AB-101) development, reduces workforce by approximately 94%, and evaluates strategic alternatives following two Grade 5 safety events and insufficient clinical durability.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest